Nucleus plus
  • Patient Care
  • About
 
 

06.21.22

Complex Genomic Features Underlying CAR T-Cell Failures in Lymphoma

by ASTCT Science Highlights

Jain MD, Ziccheddu B, Coughlin CA, et al. Whole-Genome Sequencing Reveals Complex Genomic Features Underlying Anti-CD19 CAR T-Cell Treatment Failures in Lymphoma. Blood. 2022; (doi: 10.1182/blood.2021015008).

Tumor-intrinsic genomic changes appear to contribute significantly to treatment failure in persons with large B-cell lymphomas who undergo CD19-directed chimeric antigen receptor (CAR-19) therapy. Researchers used whole-genome sequencing to study 51 tumor samples from 49 individuals matching this patient profile. Reduced expression or loss of CD19 prior to treatment had no impact on responses, raising the probability that more than one mechanism is implicated in CAR-19 treatment success or failure. In fact, the analysis identified several predictors of CAR-19 resistance — including the presence of complex structural variants, certain mutational processes, and genomic damage from reactive oxygen species. Deletion of the RHOA tumor suppressor also was associated with CAR-19 clinical failure.

Read More

Interim Analysis of KarMMa-3 Trial Finds 51% Reduction in Risk of Progression or Death with Ide-cel in RRMM
05.25.23
Interim Analysis of KarMMa-3 Trial Finds 51% Reduction in Risk of Progression or Death with Ide-cel in RRMM
by Eleanor Mayfield, ELS
IL-18-secreting anti-DLL3 CAR T cells SCLC models
05.23.23
IL-18-secreting anti-DLL3 CAR T cells SCLC models
by ASTCT Science Highlights
TCR-T cells expressing zBBΔBRM shows potent antitumor activity
05.22.23
TCR-T cells expressing zBBΔBRM shows potent antitumor activity
by ASTCT Science Highlights
footer divider

ASTCT

American Society for Transplantation
and Cellular Therapy

330 North Wabash Avenue, Suite 2000
Chicago, IL 60611, USA
Phone: (312) 321-6820
Fax: (312) 673-6733

facebook youtube twitter linkedin
Login
Search